Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"WellSpring","sponsor":"Newport Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wellspring Ophthalmics Announces Acquisition of Novel Cyclosporine Dry Eye Therapy Patent Portfolio from Newport Research","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by WellSpring

    Menu

    WellSpring

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              WellSpring

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Wellspring Ophthalmics Announces Acquisition of Novel Cyclosporine Dry Eye Therapy Patent Portfolio from Newport Research

              Details:

              Wellspring Ophthalmics’ newly acquired proprietary broad formulation platform is an innovative suspension comprising aqueous, amorphous nanodispersions of cyclosporine. These formulations are designed to have higher bioavailability for better efficacy and improved dry eye.

              Lead Product(s): Cyclosporine

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Peptide

              Recipient: Newport Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition March 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY